News to Watch: PDL BioPharma (NASDAQ:PDLI)

PDL BioPharma (NASDAQ:PDLI) spotted trading -18.77% off 52-week high price. On the other end, the stock has been noted 53.40% away from the low price over the last 52-weeks. The stock changed -8.41% to recent value of $3.16. The stock transacted 2079567 shares during most recent day however it has an average volume of 1.52M shares. The company has 119.16M of outstanding shares and 108.83M shares were floated in the market.

On March 09, 2020, PDL BioPharma (NASDAQ:PDLI) reported the appointment of Edward A. Imbrogno as the Company’s Vice President and Chief Financial Officer.

Mr. Imbrogno joined PDL as Vice President of Finance in October 2018, bringing more than 30 years of public accounting and financial reporting experience. Mr. Imbrogno was appointed as the Company’s Chief Accounting Officer in June 2019 and assumed the additional responsibilities as Acting Chief Financial Officer in November 2019. Mr. Imbrogno will continue to report to President and Chief Executive Officer, Dominique Monnet.

Since joining PDL, Ed has made highly valued contributions as leader of our finance organization and member of our senior leadership team. He is instrumental to the execution of our monetization strategy and the distribution of net proceeds to our stockholders. I look forward to our continued partnership, said Mr. Monnet.

Mr. Imbrogno will continue his duties as the Company’s Chief Accounting Officer and will receive no incremental compensation for his additional services to the Company. The change was made effective March 9, 2020.

Its earnings per share (EPS) expected to touch remained -166.30% for this year while earning per share for the next 5-years is expected to reach at 14.00%. PDLI has a gross margin of 51.10%.

According to the most recent quarter its current ratio was 9.9 that represents company’s ability to meet its current financial obligations. The price moved ahead of -10.27% from the mean of 20 days, -6.11% from mean of 50 days SMA and performed 7.34% from mean of 200 days price. Company’s performance for the week was -10.23%, -9.46% for month and YTD performance remained -2.62%.

Leave a Reply

Your email address will not be published. Required fields are marked *